| Date | Form | Description | Docs | XBRL | Pages |
| 04/09/21 | DEF 14A | Definitive proxy statements |
|
21 | |
| 04/02/21 | 8-K | Current report filing |
|
3 | |
| 03/30/21 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
22 | |
| 03/26/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 03/26/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 03/25/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 03/25/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 03/24/21 | 8-K | Current report filing |
|
25 | |
| 03/24/21 | 424B5 | Prospectus filed pursuant to Rule 424(b)(5) |
|
24 | |
| 03/23/21 | FWP | Filing under Securities Act Rules 163/433 of free writing prospectuses |
|
1 |
Latest News & Events
Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat
Read More...Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation
Read More...Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization
Read More...